EUVIMEDEUVIMED entdecken
Crossref

Short-term and long-term efficacy and safety of clobazam in pediatric refractory epilepsy: a real-world study

Cai-Xia Tu, Dan-Yang Ren, Yun-Wei Li, Jian-Ling Shen, Dong Wu, Fa-Shuang Li, Yan-Ming Yang, Qiong Zou, Hui-Ying Li

Translational Pediatrics · 2026-11 · 15 (11) · 453-453

DOI: 10.21037/tp-2026-0582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Pediatrics, 2026-11. Verfasst von Cai-Xia Tu und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although clobazam (CLB) has been approved as add-on therapy for Lennox-Gastaut syndrome (LGS) in many countries worldwide, robust evidence from clinical trials, real-world studies, and systematic reviews remains scarce. This study aimed to investigate the effectiveness and safety of CLB and influencing factors in treating refractory epilepsy (RE) in children, with the objective of improving the rational and safe application of CLB.

Methods

A self-controlled, real-world study was conducted involving pediatric patients with RE who received CLB as an adjunctive treatment at Kunming Children's Hospital in China. RE was defined in pediatric patients who did not achieve adequate seizure control with their existing anticonvulsant regimen. Data were extracted from electronic medical records and included demographic characteristics, disease profiles, treatment parameters, seizure frequency before and after CLB administration, and adverse events (AEs). The collected data were analyzed systematically using version 27.0 of the Statistical Package for the Social Sciences (SPSS).

Results

A total of 172 pediatric patients under the age of 18 years were enrolled, comprising 104 males and 68 females. The mean age at the initiation of CLB treatment was 6.61±4.16 years. The mean therapeutic dosage was 18.11±6.45 mg/day. This study evaluated the efficacy of CLB over four periods (≤3, >3 to 6, >6 to 12, and >12 months). Compared to baseline, the response rates were 80.47% (103/128), 70.00% (70/100), 67.82% (59/87), and 66.67% (40/60), respectively. Significant differences in therapeutic efficacy were identified across treatment periods, with substantially lower response rates in >6 to 12 months [odds ratio (OR)=0.357, 95% confidence interval (CI): 0.181–0.705, P=0.003] and >12 months [OR =0.259, 95% CI: 0.116–0.577, P

Zitieren

APA

Tu, C., Ren, D., Li, Y., Shen, J., Wu, D., Li, F., Yang, Y., Zou, Q., & Li, H. (2026). Short-term and long-term efficacy and safety of clobazam in pediatric refractory epilepsy: a real-world study. Translational Pediatrics, 15(11), 453-453. https://doi.org/10.21037/tp-2026-0582

Vancouver

Tu C, Ren D, Li Y, Shen J, Wu D, Li F, et al. Short-term and long-term efficacy and safety of clobazam in pediatric refractory epilepsy: a real-world study. Translational Pediatrics. 2026;15(11):453-453. doi:10.21037/tp-2026-0582

BibTeX
@article{Tu2026,
  author = {Tu, Cai-Xia and Ren, Dan-Yang and Li, Yun-Wei and Shen, Jian-Ling and Wu, Dong and Li, Fa-Shuang and Yang, Yan-Ming and Zou, Qiong and Li, Hui-Ying},
  title = {Short-term and long-term efficacy and safety of clobazam in pediatric refractory epilepsy: a real-world study},
  journal = {Translational Pediatrics},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {453--453},
  doi = {10.21037/tp-2026-0582}
}
Kostenlos starten →